SCHEMBL30689645

SCHEMBL30689645

CC(C)(C)OC(=O)N1CC(N2CCC(CN=[N+]=[N-])CC2)C1

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.42
▸ TGFBR1 P36897 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.37
▸ PKM P14618 1/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ ALDH1A1 P00352 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ HPGD P15428 1/20 0.36
▸ KEAP1 Q14145 1/20 0.35
▸ NFE2L2 Q16236 1/20 0.35
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ GPR119 Q8TDV5 2/20 0.34
▸ RECQL P46063 1/20 0.34
▸ EPHX1 P07099 1/20 0.34
▸ NAMPT P43490 1/20 0.34
▸ CCNT1 O60563 1/20 0.34
▸ CDK9 P50750 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13509914 0.87 HPGD (0.47) NR1H2TGFBR1KDM4EPKMHPGD
SCHEMBL13694467 0.85 NR1H2 (0.43) NR1H2TGFBR1KDM4EPKMMEN1
SCHEMBL26213031 0.85 NR1H2 (0.43) NR1H2TGFBR1KDM4EPKMMEN1
SCHEMBL14678793 0.85 NR1H2 (0.43) NR1H2TGFBR1KDM4EPKMMEN1
SCHEMBL14282766 0.84 NR1H2 (0.50) NR1H2TGFBR1KDM4EPKMMEN1
SCHEMBL29257891 0.80 NR1H2 (0.60) NR1H2KDM4EPKMMEN1ALDH1A1
SCHEMBL14533317 0.80 MEN1 (0.48) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL17075668 0.80 MEN1 (0.48) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL30922876 0.80 MEN1 (0.48) NR1H2MEN1ALDH1A1MAPTKMT2A
SCHEMBL22181202 0.79 NR1H2 (0.51) NR1H2KDM4EPKMMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250236607-A1 CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF OHIO STATE INNOVATION FOUNDATION 2025-07-24 — — US disclosed
EP-4499148-A1 CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF Ohio State Innovation Foundation (US) 2025-02-05 — — EP disclosed
WO-2023192534-A1 CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF OHIO STATE INNOVATION FOUNDATION (US) 2023-10-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250236607-A1 CYCLIN-DEPENDENT KINASE 9 (CDK9) DEGRADERS AND METHODS OF USING THEREOF CDK9, CDK19, CDKL2 NR1H2 3420/4885TGFBR1 4344/4885KDM4E 153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback